Background The majority of available data on molnupiravir come from an unvaccinated
COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …

Importance Older patients living in nursing homes are at very high risk of mortality after
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …

Antiviral therapeutics for COVID-19 in nonhospitalized patients prevent progression to
severe illness, hospitalization, and death. Despite their proven benefit, utilization of these …

Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We
identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …